Matches in DBpedia 2016-04 for { ?s ?p "ARIAD Pharmaceuticals, Inc. is an oncology company founded in 1991 and headquartered in Cambridge, Massachusetts. On December 14, 2012 the FDA approved Ariad Pharmaceutical’s leukemia drug Iclusig for patients with all forms of chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia who are resistant or unable to tolerate other tyrosine kinase therapies on the market."@en }
Showing triples 1 to 4 of
4
with 100 triples per page.
- ARIAD_Pharmaceuticals abstract "ARIAD Pharmaceuticals, Inc. is an oncology company founded in 1991 and headquartered in Cambridge, Massachusetts. On December 14, 2012 the FDA approved Ariad Pharmaceutical’s leukemia drug Iclusig for patients with all forms of chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia who are resistant or unable to tolerate other tyrosine kinase therapies on the market.".
- Q4653724 abstract "ARIAD Pharmaceuticals, Inc. is an oncology company founded in 1991 and headquartered in Cambridge, Massachusetts. On December 14, 2012 the FDA approved Ariad Pharmaceutical’s leukemia drug Iclusig for patients with all forms of chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia who are resistant or unable to tolerate other tyrosine kinase therapies on the market.".
- ARIAD_Pharmaceuticals comment "ARIAD Pharmaceuticals, Inc. is an oncology company founded in 1991 and headquartered in Cambridge, Massachusetts. On December 14, 2012 the FDA approved Ariad Pharmaceutical’s leukemia drug Iclusig for patients with all forms of chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia who are resistant or unable to tolerate other tyrosine kinase therapies on the market.".
- Q4653724 comment "ARIAD Pharmaceuticals, Inc. is an oncology company founded in 1991 and headquartered in Cambridge, Massachusetts. On December 14, 2012 the FDA approved Ariad Pharmaceutical’s leukemia drug Iclusig for patients with all forms of chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia who are resistant or unable to tolerate other tyrosine kinase therapies on the market.".